MedX Health Corp. Announces Brokered Private Placement
23 1월 2014 - 12:18AM
Marketwired
MedX Health Corp. Announces Brokered Private Placement
MISSISSAUGA, ONTARIO--(Marketwired - Jan 22, 2014) - MedX Health
Corp. ("MedX" or the "Company") (TSX-VENTURE:MDX) announces the
engagement of Trapeze Capital Corp., as lead agent (the "Agent"),
to raise gross proceeds of up to $2.0 million, from accredited
investors, on a reasonable efforts basis through a private
placement of Units, with each Unit comprised of one Common Share
and one Common Share Purchase Warrant ('Warrant") (the "Offering")
at $0.10 per Unit. Each Warrant will entitle the holder to purchase
one Common Share during the period ending two years from the date
of issue, at an exercise price of $0.20.
Closing of the Offering will be subject to receipt of
subscriptions and also a number of conditions, including the
receipt of all relevant regulatory and other consents and
approvals, including that of the TSX Venture Exchange, as well as
the negotiation and execution of certain documentation, including
an agency agreement between the Agent and MedX. Closing of the
Offering is expected to take place in late February.
At closing, MedX will pay the Agent a cash commission equal to
8% of the aggregate proceeds of the Units sold, and will issue
broker warrants to the Agent to acquire that number of common
shares equal to 8% of the number of common shares that comprise the
Units sold by the agent under the Offering. Each broker warrant
will be exercisable at $0.20 per share for a period of two years
after closing. As well, MedX will pay the Agent's reasonable
expenses incurred in connection with the Offering.
The net proceeds from sale of the Units will be used for the
expansion of marketing efforts of the Company's products, and for
general working capital purposes. All securities issued in
conjunction with the Offering will be subject to a four-month and
one day hold period under applicable securities laws and the
policies of the TSX Venture Exchange.
About MedX
MedX is headquartered in Mississauga, Ontario (Toronto), and is
a global leader in the design, manufacturing and distribution of
quality low level laser and light therapy technologies for use in
numerous medical settings, including rehab/chiropractic, dental,
wound care, and veterinary medicine, providing patients with drug
free and non-invasive treatment of tissue damage and pain. MedX
laser and light products are FDA approved, Health Canada cleared,
and CE Mark approved for use in North America as well as the
European Union. MedX's products include SIMSYS™ and MoleMate™,
which are approved by Health Canada, and available to Canadian
physicians and dermatologists, are FDA approved for use in the USA
and are currently under review for CE approval for use in Europe,
the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for
clinical use that utilizes light to view beneath suspicious moles
or lesions in a pain free, non-invasive manner, creating images in
real-time for physicians and dermatologists to evaluate all types
of moles or lesions within seconds. For more information log onto:
www.simsys-molemate.com. For a complete profile of MedX and its
products visit www.medxhealth.com.
This press release does not constitute an offer of any
securities for sale. This press release contains certain
forward-looking statements within the meaning of applicable
Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual
results to differ, including, without limitation, the company's
limited operating history and history of losses, the inability to
successfully obtain further funding, the inability to raise capital
on terms acceptable to the company, the inability to compete
effectively in the marketplace, the inability to complete the
proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the
company's projections or forward-looking statements. All forward
looking statements in this press release are based on information
available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to
reflect events or circumstances occurring after the date of this
press release.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
MedX Health Corp.Robert von der PortenPresident and CEO905 670
4428investor@medxhealth.comwww.medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024